Nothing Special   »   [go: up one dir, main page]

IN2014DN08236A - - Google Patents

Download PDF

Info

Publication number
IN2014DN08236A
IN2014DN08236A IN8236DEN2014A IN2014DN08236A IN 2014DN08236 A IN2014DN08236 A IN 2014DN08236A IN 8236DEN2014 A IN8236DEN2014 A IN 8236DEN2014A IN 2014DN08236 A IN2014DN08236 A IN 2014DN08236A
Authority
IN
India
Prior art keywords
fusion molecules
ifn
present
engineered
fusion
Prior art date
Application number
Inventor
Iqbal Grewal
Sanjay D Khare
Michael Gresser
Rashid Syed
Original Assignee
Immungene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immungene Inc filed Critical Immungene Inc
Publication of IN2014DN08236A publication Critical patent/IN2014DN08236A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

The field of the present invention relates to genetically engineered fusion molecules methods of making said fusion molecules and uses thereof in anti tumor immunotherapies. More specifically the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments the engineered fusion molecules comprise a TAA Ab fused to an interferon alpha (IFN a) mutant molecule. The engineered Ab IFN a mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab wildtype IFN a fusion molecules and/or demonstrate improved PK properties as compared to Ab wildtype IFN a fusion molecules.
IN8236DEN2014 2012-03-03 2013-03-04 IN2014DN08236A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261634565P 2012-03-03 2012-03-03
PCT/US2013/028899 WO2013134138A1 (en) 2012-03-03 2013-03-04 Engineered antibody-interferon mutant fusion molecules

Publications (1)

Publication Number Publication Date
IN2014DN08236A true IN2014DN08236A (en) 2015-05-15

Family

ID=49042962

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8236DEN2014 IN2014DN08236A (en) 2012-03-03 2013-03-04

Country Status (15)

Country Link
US (3) US8980267B2 (en)
EP (2) EP3799880A3 (en)
JP (1) JP6195855B2 (en)
CN (1) CN104470536A (en)
AU (1) AU2013230484B2 (en)
CA (1) CA2866126A1 (en)
DK (1) DK2822575T3 (en)
ES (1) ES2800426T3 (en)
HR (1) HRP20200918T1 (en)
HU (1) HUE049945T2 (en)
IN (1) IN2014DN08236A (en)
LT (1) LT2822575T (en)
PL (1) PL2822575T3 (en)
PT (1) PT2822575T (en)
WO (1) WO2013134138A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5591701B2 (en) * 2007-09-21 2014-09-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Targeted interferon with potent apoptotic and antitumor activity
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
NZ756727A (en) 2011-10-28 2022-12-23 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
KR102050119B1 (en) 2012-01-20 2019-11-28 브이아이비 브이지더블유 Targeted mutant alpha-helical bundle cytokines
US9803021B2 (en) * 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
CN105473615B (en) 2013-04-29 2019-05-07 泰华制药澳大利亚公司 Anti-cd 38 antibodies and with cause weak jamming element α -2B fusion
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
JP6580037B2 (en) 2013-07-18 2019-09-25 ヴィブ ブイゼットダブリュー Fusokines containing cytokines with highly reduced receptor binding affinity
EP3021865B1 (en) 2013-07-19 2018-06-13 Vib Vzw Targeted modified tnf family members
JP6475712B2 (en) 2013-07-19 2019-02-27 ヴィブ ブイゼットダブリュー Targeting cytokine antagonists
JP6475713B2 (en) 2013-07-19 2019-02-27 ヴィブ ブイゼットダブリュー Target-modified IL-1 family members
CN104193828B (en) * 2013-09-12 2017-04-05 北京韩美药品有限公司 The recombination fusion protein of HER2 and VEGFR signal paths is blocked simultaneously
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
UA119352C2 (en) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof
CA2965414C (en) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
WO2016201350A1 (en) * 2015-06-12 2016-12-15 Immungene, Inc. Combination therapy for treatment of cancer
WO2016201337A1 (en) * 2015-06-12 2016-12-15 Immungene, Inc. Engineered antibody-interferon fusion molecules for the treatment of glucose-regulated protein 94 (grp94) expressing cancers
WO2016201251A1 (en) * 2015-06-12 2016-12-15 Immungene, Inc. Focused interferon immunotherapy for treatment of cancer
US20190008983A1 (en) * 2015-07-31 2019-01-10 James R. Prudent Extracellular drug conjugates targeting cd20
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
WO2017091611A1 (en) * 2015-11-23 2017-06-01 Immungene, Inc Enhanced cancer immunotherapy using antibody-interferon fusion molecules
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN109071632B (en) 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 Targeted therapeutic agents and uses thereof
JP2019507762A (en) 2016-03-07 2019-03-22 ブイアイビー ブイゼットダブリュー CD20 binding single domain antibody
US20190119403A1 (en) * 2016-03-31 2019-04-25 University Of Southern California Methods of constructing immunoglobulin fusion proteins inhibiting cathepsin b and compositions thereof
WO2017180764A1 (en) * 2016-04-12 2017-10-19 Immungene, Inc. Focused interferon immunotherapy
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
EP3454887B1 (en) 2016-05-13 2021-01-20 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof
JP7204643B2 (en) 2016-10-24 2023-01-16 オリオニス バイオサイエンシズ ビーブイ Targeted mutant interferon-gamma and its uses
CN106854248A (en) * 2016-12-09 2017-06-16 中国药科大学 A kind of preparation and its application of cell factor mutant fusion antibody
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
AU2018216032B2 (en) 2017-02-06 2022-04-07 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
CA3050601A1 (en) * 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
CA3068256A1 (en) * 2017-06-21 2018-12-27 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
EP3649147A4 (en) * 2017-07-03 2021-04-14 Torque Therapeutics, Inc. Polynucleotides encoding immunostimulatory fusion molecules and uses thereof
AU2018307752A1 (en) * 2017-07-24 2020-03-12 Rutgers, The State University Of New Jersey Phosphatidylserine targeting fusion molecules and methods for their use
AU2018313810A1 (en) 2017-08-09 2020-02-27 Orionis Biosciences BV Clec9A binding agents and use thereof
JP7347899B2 (en) 2017-08-09 2023-09-20 オリオンズ バイオサイエンス インコーポレイテッド CD8 binding substance
US11498966B2 (en) 2017-08-09 2022-11-15 Orionis Biosciences Inc. PD-1 and PD-L1 binding agents
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
CN107556376B (en) * 2017-09-08 2018-09-28 上海华新生物高技术有限公司 A kind of Interferon Alpha-2b mutant and its preparation method and application
WO2019191519A1 (en) * 2018-03-28 2019-10-03 Orionis Biosciences, Inc. Bi-functional proteins and construction thereof
EP3833391A4 (en) 2018-08-08 2022-08-10 Orionis Biosciences, Inc. SIRP1alpha TARGETED CHIMERIC PROTEINS AND USES THEREOF
CN111499718B (en) * 2019-01-30 2022-06-14 复旦大学 Human alpha interferon receptor binding related site mutant and application thereof
CN109884313A (en) * 2019-02-22 2019-06-14 武汉康圣达医学检验所有限公司 The detection kit of B-lineage Acute Lymphocyte Leukemia minimal residual
CN113840833A (en) * 2019-03-28 2021-12-24 奥里尼斯生物科学股份有限公司 CLEC 9A-based chimeric protein complex
CA3133643A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins
AU2020258384A1 (en) 2019-04-15 2021-11-04 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer
WO2021136240A1 (en) * 2019-12-30 2021-07-08 白素梅 Mutant coding gene of human 4igb7-h3 and use thereof in regulating immunity
AU2022326107A1 (en) * 2021-08-12 2024-03-14 Shanghai Ttm-Bio Technology Co., Ltd. Bispecific recombinant protein and use thereof
CN114163522A (en) * 2021-12-07 2022-03-11 重庆市动物疫病预防控制中心 Nano antibody capable of identifying porcine pseudorabies virus with high accuracy and sensitivity, preparation method and application

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1981A (en) 1841-02-18 backus
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
FR2504010B1 (en) 1981-04-15 1985-10-25 Sanofi Sa ANTI-CANCER MEDICINAL PRODUCTS CONTAINING THE RICIN-ASSOCIATED CHAIN ASSOCIATED WITH ANTIMELANOMA ANTIBODY AND PROCESS FOR THEIR PREPARATION
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0092227B1 (en) 1982-04-19 1988-07-27 Nissan Motor Co., Ltd. Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
WO2001058957A2 (en) * 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US8435529B2 (en) * 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
EP1594965A2 (en) 2003-02-18 2005-11-16 MERCK PATENT GmbH Fusion proteins of interferon alpha muteins with improved properties
CN1902222A (en) * 2003-12-31 2007-01-24 默克专利有限公司 Fc-erythropoietin fusion protein with improved pharmacokinetics
US20090005297A1 (en) * 2004-07-13 2009-01-01 Kevin Lumb Aprotinin Variants
MX2007001589A (en) * 2004-08-09 2007-08-02 Alios Biopharma Inc Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same.
BRPI0609809A2 (en) 2005-05-18 2011-10-11 Maxygen Inc isolated or recombinant polypeptide, conjugate, composition, isolated or recombinant polynucleotide, host cell, vector, methods for preparing the polypeptide, for preparing a conjugate, for inhibiting virus replication in virus-infected cells to reduce the number of copies of a virus in virus-infected cells, to reduce hcv rna level in serum of an hcv infected patient, to reduce hbv dna level in serum of an hbv infected patient, and to reduce hiv rna level in serum from an HIV-infected patient, and use of the polypeptide or conjugate
EA014157B1 (en) * 2005-06-29 2010-10-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. RECOMBINANT INTERFERON α2 (IFNα2) MUTANTS
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
JP5591701B2 (en) * 2007-09-21 2014-09-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Targeted interferon with potent apoptotic and antitumor activity
GEP201706660B (en) * 2010-03-04 2017-04-25 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
BR112012023053A2 (en) * 2010-03-12 2017-07-25 Forage Innovations Bv "agricultural machine, mower and method for guiding a rear gearbox into a mower"
EP3135692B8 (en) * 2010-06-16 2019-03-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Antibodies to endoplasmin and their use
NZ756727A (en) 2011-10-28 2022-12-23 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
KR102050119B1 (en) 2012-01-20 2019-11-28 브이아이비 브이지더블유 Targeted mutant alpha-helical bundle cytokines
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
CN105473615B (en) 2013-04-29 2019-05-07 泰华制药澳大利亚公司 Anti-cd 38 antibodies and with cause weak jamming element α -2B fusion

Also Published As

Publication number Publication date
WO2013134138A1 (en) 2013-09-12
AU2013230484B2 (en) 2017-04-27
DK2822575T3 (en) 2020-06-15
JP6195855B2 (en) 2017-09-13
EP2822575A1 (en) 2015-01-14
CA2866126A1 (en) 2013-09-12
HUE049945T2 (en) 2020-11-30
US20170073388A1 (en) 2017-03-16
US20150139951A1 (en) 2015-05-21
US8980267B2 (en) 2015-03-17
HRP20200918T1 (en) 2020-11-27
EP2822575A4 (en) 2016-07-06
ES2800426T3 (en) 2020-12-30
EP2822575B1 (en) 2020-05-06
AU2013230484A1 (en) 2015-02-12
PL2822575T3 (en) 2020-08-10
CN104470536A (en) 2015-03-25
US20130230517A1 (en) 2013-09-05
EP3799880A2 (en) 2021-04-07
US10259854B2 (en) 2019-04-16
JP2015515453A (en) 2015-05-28
EP3799880A3 (en) 2021-06-23
US9534057B2 (en) 2017-01-03
LT2822575T (en) 2020-06-25
PT2822575T (en) 2020-07-02

Similar Documents

Publication Publication Date Title
IN2014DN08236A (en)
CY1122165T1 (en) ANTI-CD38 ANTIBODIES
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
CY1121466T1 (en) ANTIBODIES AGAINST B1 VRADYKININ RECEPTORS
EP4219536A3 (en) Targeted/immunomodulatory fusion proteins and methods for making same
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
EP2675474A4 (en) Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
MX2021008463A (en) Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics.
WO2014062697A3 (en) Drug delivery conjugates containing unnatural amino acids and methods for using
EP2496607A4 (en) Vault complexes for cytokine delivery
MX339239B (en) Anti-cd40 antibodies and methods of use.
MX341076B (en) Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments.
EA201390145A1 (en) CONJUGATES, PARTICLES, COMPOSITIONS AND RELATED METHODS
MX366130B (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same.
MX352738B (en) Cytotoxic peptides and antibody drug conjugates thereof.
MX2019002979A (en) Antibody formulations.
EA201790109A1 (en) TOLEROGENIC SYNTHETIC NANO-MEDIA DECREASING IMMUNE RESPONSE TO THERAPEUTIC PROTEINS
NZ701573A (en) Carriers for improved drug delivery
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2015012808A (en) Cd20-binding immunotoxins for inducing cellular internalization and methods using same.
MX2013010286A (en) Amatoxin-conjugates with improved linkages.
MY170719A (en) Antibody-drug conjugates
PH12014501103A1 (en) Methods of treating epidermal growth factor deletion mutant viii related disorders
RS53713B1 (en) Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells